The AHA today urged the Departments of the Treasury, Labor and Health and Human Services to not finalize a proposed rule that would allow certain grandfathered health plans to increase patient cost-sharing beyond current limits without losing their grandfathered status.

The proposed rule would allow grandfathered plans more flexibility to increase fixed cost-sharing amounts (e.g., copays, deductibles and out-of-pocket maximums) without losing their grandfathered status, including allowing grandfathered plans that are high-deductible health plans to increase their fixed-amount cost-sharing beyond the allowed amounts if doing so is necessary for compliance with the HDHP requirements.

The AHA expressed concerns about the financial burden these plans put on patients, noting that it harms patients who may avoid accessing necessary care.

“At a time when access to health care is more critical than ever, we urge the departments not to finalize this rule, which could decrease patients’ health care coverage,” AHA wrote, while highlighting the added impact of undermining the financial stability of the hospitals and health systems that serve them.

Related News Articles

Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
The Office for Civil Rights in the Department of Health and Human Services Dec. 5 issued a letter to health care providers and others clarifying language…
Headline
The Congressional Budget Office Dec. 5 informed Congress that 2.2 million consumers would lose their health insurance in 2026 if enhanced premium subsidies are…
Perspective
December’s holiday rush is in full swing on Capitol Hill as Congress returned to Washington this week facing a long list of to-dos and a short time to do them…
Headline
Approximately 988,000 consumers who currently do not have health insurance coverage through the individual marketplace have signed up for a 2025 health plan…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex…